Published in J Immunol on June 01, 1983
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol (1997) 4.65
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol (2003) 2.91
Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun (2001) 2.86
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
The structure and function of human IgA. Biochem J (1990) 2.65
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun (1995) 2.44
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev (1998) 1.81
Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol (2001) 1.57
Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44
Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin Microbiol Rev (1989) 1.29
Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev (1993) 1.26
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol (2013) 1.23
Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect Immun (1998) 1.19
Meningococcal disease and the complement system. Virulence (2013) 1.19
Opsonization of yeast by human serum IgA anti-mannan antibodies and phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol (1987) 1.08
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis. Infect Immun (2005) 1.06
Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun (1995) 1.05
Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing. Infect Immun (1995) 1.05
Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun (1999) 1.03
Structural analysis of the N-glycans from human immunoglobulin A1: comparison of normal human serum immunoglobulin A1 with that isolated from patients with rheumatoid arthritis. Biochem J (1994) 1.00
Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol (2011) 0.99
Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura. J Clin Invest (1991) 0.97
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol (2004) 0.97
Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun (1997) 0.96
Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines (2013) 0.90
Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun (2004) 0.90
T and B cell responses following immunization with tetanus toxoid in IgA nephropathy. Clin Exp Immunol (1992) 0.90
Identification and characterization of IgA and Vicia villosa-binding T cell subsets in rheumatoid arthritis. Clin Exp Immunol (1990) 0.88
Effect of human immunodeficiency virus infection on plasma bactericidal activity against Salmonella enterica serovar Typhimurium. Clin Vaccine Immunol (2014) 0.83
Opsonic effect of jacalin and human immunoglobulin A on type II group B streptococci. Infect Immun (1990) 0.82
Antibody responses to Bordetella bronchiseptica in vaccinated and infected dogs. Can Vet J (2014) 0.82
HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res (2013) 0.80
IgA against gut-derived endotoxins: does it contribute to suppression of hepatic inflammation in alcohol-induced liver disease? Dig Dis Sci (2002) 0.78
Immunoresponses to Neisseria meningitidis epitopes: suppression of secondary response to phosphorylcholine is carrier specific. Infect Immun (1986) 0.78
A human T-cell receptor recognizes 'O'-linked sugars from the hinge region of human IgA1 and IgD. Immunology (1994) 0.76
Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev (2017) 0.76
New prospects for a preventive HIV-1 vaccine. J Virus Erad (2015) 0.75
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest (1979) 3.61
Heterogeneity of molecular size and antigenic expression within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis. Infect Immun (1984) 3.33
Immunological basis of serum resistance of Neisseria gonorrhoeae. J Gen Microbiol (1982) 2.66
In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation. J Exp Med (1990) 2.61
Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides. Infect Immun (1986) 2.55
Phenotypic variation in epitope expression of the Neisseria gonorrhoeae lipooligosaccharide. Infect Immun (1987) 2.34
Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J Infect Dis (1990) 2.22
Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men. J Exp Med (1991) 2.22
Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol (1991) 2.19
Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol (1975) 2.15
Comparison of bacteriological methods for the isolation of group of B Streptococcus from vaginal cultures. J Clin Microbiol (1976) 2.14
Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun (1988) 2.06
The structural basis for pyocin resistance in Neisseria gonorrhoeae lipooligosaccharides. J Biol Chem (1991) 2.05
Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease. J Infect Dis (1977) 1.96
Elaboration of a 3.6-kilodalton lipooligosaccharide, antibody against which is absent from human sera, is associated with serum resistance of Neisseria gonorrhoeae. Infect Immun (1985) 1.93
Investigation of the structural heterogeneity of lipooligosaccharides from pathogenic Haemophilus and Neisseria species and of R-type lipopolysaccharides from Salmonella typhimurium by electrospray mass spectrometry. J Bacteriol (1993) 1.81
Vaginal colonization with group B streptococcus: a study in college women. J Infect Dis (1977) 1.76
Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect Immun (1987) 1.67
Bactericidal antibody response of normal human serum to the lipooligosaccharide of Neisseria gonorrhoeae. J Infect Dis (1986) 1.66
Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Methods Enzymol (1994) 1.64
Instability of expression of lipooligosaccharides and their epitopes in Neisseria gonorrhoeae. Infect Immun (1988) 1.62
Structural models for the cell surface lipooligosaccharides of Neisseria gonorrhoeae and Haemophilus influenzae. Biomed Environ Mass Spectrom (1990) 1.60
Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol (1991) 1.57
Structural characterization of the cell surface lipooligosaccharides from a nontypable strain of Haemophilus influenzae. Biochemistry (1992) 1.56
Immunoepidemiology of meningococcal disease in military recruits. I. A model for serogroup independency of epidemic potential as determined by serotyping. J Infect Dis (1977) 1.54
Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis (1982) 1.53
Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med (1987) 1.53
Structural determination of oligosaccharides derived from lipooligosaccharide of Neisseria gonorrhoeae F62 by chemical, enzymatic, and two-dimensional NMR methods. Biochemistry (1991) 1.49
Production of BSF-1 during an in vivo, T-dependent immune response. J Immunol (1986) 1.47
Does ozone alleviate AIDS diarrhea? J Clin Gastroenterol (1993) 1.47
Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular and class 1, 2, and 3 protein epitopes. Infect Immun (1989) 1.42
A bactericidal microassay for testing serum sensitivity of Neisseria gonorrhoeae. J Immunol Methods (1982) 1.42
Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis. Infect Immun (1988) 1.41
Structure and heterogeneity of the oligosaccharides from the lipopolysaccharides of a pyocin-resistant Neisseria gonorrhoeae. Proc Natl Acad Sci U S A (1989) 1.41
Structural studies of the lipooligosaccharides from Haemophilus influenzae type b strain A2. Biochemistry (1993) 1.41
Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis (1984) 1.41
Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun (1997) 1.37
Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect Immun (1981) 1.37
Response to antigenic determinants of Neisseria meningitidis lipopolysaccharide investigated with a new radioactive antigen-binding assay. J Immunol (1976) 1.35
IgA-dependent, monocyte-mediated, antibacterial activity. J Exp Med (1980) 1.29
In vitro and in vivo B lymphocyte-activating properties of monoclonal anti-delta antibodies. I. Determinants of B lymphocyte-activating properties. J Immunol (1986) 1.27
Stability of expression of Neisseria gonorrhoeae lipooligosaccharides. Infect Immun (1986) 1.25
Effect of exogenous sialylation of the lipooligosaccharide of Neisseria gonorrhoeae on opsonophagocytosis. Infect Immun (1992) 1.24
Sialylation and human neutrophil killing of group C Neisseria meningitidis. J Infect Dis (1992) 1.24
Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest (1992) 1.22
Use of transformation to construct Neisseria gonorrhoeae strains with altered lipooligosaccharides. Infect Immun (1988) 1.22
Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis (1996) 1.21
Group A meningococcal disease in the U.S. Pacific Northwest: epidemiology, clinical features, and effect of a vaccination control program. Rev Infect Dis (1984) 1.21
Antibody-dependent mononuclear cell-mediated antimeningococcal activity. Comparison of the effects of convalescent and postimmunization immunoglobulins G, M, and A. J Clin Invest (1980) 1.20
Immunochemical characterization of native polysaccharides from group B streptococcus: the relationship of the type III and group B determinants. J Immunol (1978) 1.18
Clinical correlation of strain differentiation of Neisseria gonorrhoeae. J Infect Dis (1976) 1.13
Neuraminic acid is alpha 2-->3 linked in the lipooligosaccharide of Neisseria meningitidis serogroup B strain 6275. J Bacteriol (1993) 1.10
Epitope expression of gonococcal lipooligosaccharide (LOS). Importance of the lipoidal moiety for expression of an epitope that exists in the oligosaccharide moiety of LOS. Mol Immunol (1988) 1.09
Adult meningoencephalitis caused by herpesvirus hominis type 2. Am J Med (1974) 1.08
Detection and some properties of the sialyltransferase implicated in the sialylation of lipopolysaccharide of Neisseria gonorrhoeae. Microb Pathog (1993) 1.07
Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing. Infect Immun (1995) 1.05
Human IgA1 initiates complement-mediated killing of Neisseria meningitidis. J Immunol (1989) 1.04
Distribution of a lipooligosaccharide-specific sialyltransferase in pathogenic and non-pathogenic Neisseria. Microb Pathog (1993) 1.03
Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers. Sex Transm Dis (2001) 1.03
Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide. Infect Immun (1990) 1.00
Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun (1982) 1.00
Localization of host immunoglobulin G to the surface of Pneumocystis carinii. Infect Immun (1990) 0.98
Epidemiological value of lipopolysaccharide and heat-modifiable outer-membrane protein serotyping of group-A strains of Neisseria meningitidis. J Med Microbiol (1982) 0.97
Pigment gallstone pathogenesis: slime production by biliary bacteria is more important than beta-glucuronidase production. J Gastrointest Surg (2000) 0.97
Elaboration of both the group W135 and group Y capsular polysccharides by a single strain of Neisseria meningitidis. J Gen Microbiol (1980) 0.97
Methods for the collection of peritoneal and alveolar macrophages. Methods Enzymol (1984) 0.96
In vitro differentiation of human-derived Pneumocystis carinii. J Clin Microbiol (1989) 0.95
Group A meningococcal disease in skid rows: epidemiology and implications for control. Am J Public Health (1984) 0.94
Neisseria gonorrhoeae that infect men have lipooligosaccharides with terminal N-acetyllactosamine repeats. J Biol Chem (1999) 0.94
Biologic function of the serum IgA system: modulation of complement-mediated effector mechanisms and conservation of antigenic mass. Ann N Y Acad Sci (1983) 0.94
Ability of gonococcal and meningococcal lipooligosaccharides to clot Limulus amebocyte lysate. Infect Immun (1992) 0.93
Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora. J Clin Microbiol (1985) 0.93
Separation and purification of immunoglobulins M,A and G from small volumes of human sera by a continuous, inline chromatographic process. J Chromatogr (1978) 0.93
Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions. Clin Diagn Lab Immunol (1995) 0.91
Immunological cross-reaction between a naturally occurring galactan, agarose, and an LPS locus for immune lysis of Neisseria meningitidis by human sera. Clin Exp Immunol (1981) 0.90
Vaccines against encapsulated bacteria: a global agenda. Rev Infect Dis (1987) 0.90
Heterogenity of serotypes of Neisseria meningitidis that cause endemic disease. J Infect Dis (1979) 0.89
Influence of age on serogroup distribution of endemic meningococcal disease. Pediatrics (1983) 0.89
Meningococcal group A lipooligosaccharides (LOS): preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes. Infect Immun (1994) 0.89
Differences in outer membrane characteristics between gallstone-associated bacteria and normal bacterial flora. Lancet (1994) 0.88
The immune response of children to meningococcal lipooligosaccharides during disseminated disease is directed primarily against two monoclonal antibody-defined epitopes. J Infect Dis (1993) 0.88
Correlation of Pneumocystis carinii cyst density with mortality in patients with acquired immunodeficiency syndrome and pneumocystis pneumonia. Hum Pathol (1992) 0.87
CEACAM is not necessary for Neisseria gonorrhoeae to adhere to and invade female genital epithelial cells. Cell Microbiol (2001) 0.87
Vaccination against meningococcal disease. N Engl J Med (1983) 0.86
Immunophysical characterization of human isolates of Serratia marcescens. J Clin Microbiol (1990) 0.86
Pneumocystis carinii in sputum. Comparable efficacy of screening stains and determination of cyst density. Arch Pathol Lab Med (1988) 0.86
Serum IgA: modulation of complement activation and induction of susceptibility to bacterial dissemination. Infection (1982) 0.84
Disease due to serogroup W135 Neisseria meningitidis. Pediatrics (1979) 0.83
Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis. Infect Immun (2000) 0.82
Relationship of dose to the reactogenicity and immunogenicity of meningococcal polysaccharide vaccines in adults. Mil Med (1985) 0.81
Results of vaccination in patients with IgA deficiency and/or IgG subclass deficiencies. Ann Sclavo Collana Monogr (1986) 0.79
Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, phase III multicenter studies. J Clin Oncol (1998) 0.79
Mucosal and serum immunity following commensal enteric colonization. Adv Exp Med Biol (1987) 0.79